Bioanalysis
Bioanalytical Platform Selection for Your Molecule
Renowned for our expertise with LC-MS/MS and Ligand Binding platforms, Altasciences can help you expedite your research goals by efficiently determining which bioanalytical platform is most appropriate for your molecule― from discovery, to preclinical safety testing, to first-in-human trials, and beyond. |
|
With Altasciences' in-house database of over 680 validated assays, as well as the ability to provide customized workflows and methods using advanced instrumentation and various bioanalytical platforms, we can help you make the right decision. |
Bioanalytical Expertise in ASO Quantification
How Can We Help
Analysis of Fenfluramine and Norfenfluramine in Mouse Brain and Cerebellum by Liquid Chromatography Tandem Mass Spectrometry using a Novel Solid-Supported Liquid Extraction
Answers to your questions on the development of biologics and biosimilars
Bioanalytical Solutions Throughout the Drug Development Continuum
Leverage Altasciences' preclinical and clinical bioanalytical expertise to accelerate your drug development programs. We have been delivering premium bioanalytical services to global pharma and biotech companies for over 25 years. We take pride in the diversity, expertise, and bandwidth of our scientific team, many of whom are industry-recognized bioanalytical subject matter experts. From de novo development to rugged and robust validated assays, you can rely on our experience to help you reach your milestones. With Altasciences, you can rest easy knowing that your studies are conducted in our state-of-the art laboratories, either in the U.S. or Canada, whether for small or large molecule programs, using ligand binding or mass spectrometry platforms. In addition, each bioanalytical project is assigned a scientist with whom you can communicate directly, for efficient and effective project progression. |
Detection of Peripheral Blood Foxp3+ Regulatory T Cell Population in a Preclinical Setting
Translatability of Non-Human Primate Cytokine Data to In-Life Parameters in Nonclinical
Quantitative Bioanalysis of Rituximab and Reditux for Biosimilarity Assessment: Comparing Triple Quadrupole and Hybrid Time-of-Flight Platforms
A Sensitive LC-HRMS Method for the Quantitation of Dystrophin in Human Muscle Tissue